Please assess the completion status of the following clinical trial:

Trial Title: Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 14\~60 years old~* Allogenic hematological stem cell transplantation(HSCT) patients.~* Cardiac ejection factor ≥ normal upper limit, Aspartate aminotransferase and/or Alanine aminotransferase \< 2 upper limit of normal, and/or total bilirubin \< 2.5 upper limit of normal, creatinine \< upper limit of normal.~* Informed consent.~Exclusion Criteria:~* Evidence of proven, probable or possible fungal infection at the time of enrollment.~* Patients were receiving anti-fungal treatment with proven SFI before transplantation.~* A history of hypersensitivity to G-CSF or GM-CSF.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhGM-CSF group (Type: EXPERIMENTAL): subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily
- rhG-CSF+rhGM-CSF group (Type: ACTIVE_COMPARATOR): a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each
- rhG-CSF group (Type: ACTIVE_COMPARATOR): subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).